Note from our CEO

Note from our CEO

As I reflect on the year gone by, it has been challenging for all businesses globally. My team at Cellomatics Biosciences have been extremely resilient and have fought back all the challenges posed by 2020. We have all therefore emerged unscathed and victorious. Despite the uncertainties for most part of 2020, my team stayed motivated and driven for new challenges. This makes me extremely proud and I dedicate this year’s success to my fantastic Cellomatics’ team.

Over the last 12 months, we have successfully delivered 50 projects in collaboration with 20 sponsors. This has been only possible due to the continued support from our sponsors. I would therefore like to take this opportunity to thank all our clients for trusting us and giving us the opportunity to be part of their growth journey. We look forward to supporting your research programme in the coming years.

Our aim is to constantly identify ways to add value to all our client discovery projects. We achieve this by regularly reviewing and evaluating new technologies that complement and augment our preclinical in vitro capabilities. This year Cellomatics BioSciences Ltd. invested in two equipments, The ImageXpress® Pico Automated Cell Imaging System and 2020 Attune NxT Flow Cytometer, to cater to the experimental needs of our expanding client network.

In the New Year there are plans to broaden our service offerings and to create more jobs. Over the next few months please look out for additional updates in our News section:  https://www.cellomaticsbio.com/news-events/

Thank you all. Have a safe Christmas and best wishes for a bright start to the New year.

Best regards,

Shailendra Singh

Founder and CEO – Cellomatics Biosciences

Get a consultation today

We offer more possibilities to meet your every need.
Cellomatics Biosciences Ltd Logo
Cellomatics Biosciences Ltd. is a specialised Contract Research Organisation (CRO) providing bespoke preclinical laboratory based services.

Contact Details